Aastyn Guarino
Medical · Lansing, MINPI 1013630516
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 873 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Johnson & Johnson at 24.4% of the total. 2025 is the largest year on record at $5,403, 6.4 times the $843 reported in 2022. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 873 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- AbbVie$2K
- UCB, Inc.$2K
- Amgen$2K
- AstraZeneca$851
- Novartis$609
- plus $4K from 27 others
What the payments were for
- Food & beverage$14,91496%
- Education$5494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 351 | $3,775 |
| AbbVie | 136 | $2,356 |
| UCB, Inc. | 71 | $1,896 |
| Amgen(2 entities) | 71 | $1,655 |
| AstraZeneca(2 entities) | 34 | $851 |
| Novartis | 26 | $609 |
| ANI Pharmaceuticals, Inc. | 26 | $576 |
| Mallinckrodt Hospital Products Inc. | 24 | $532 |
| Organon | 19 | $369 |
| Lilly USA, LLC | 14 | $298 |
| United Therapeutics Corporation | 4 | $287 |
| E.r. Squibb & Sons, L.L.C. | 12 | $286 |
| Boehringer Ingelheim | 11 | $238 |
| Fresenius Kabi USA, LLC | 10 | $211 |
| Janssen Scientific Affairs, LLC | 2 | $208 |
| Sobi, Inc | 10 | $203 |
| Sanofi | 5 | $184 |
| Sandoz | 8 | $175 |
| Alvogen Inc | 7 | $126 |
| Actelion Pharmaceuticals US, Inc. | 5 | $124 |
| Merck | 4 | $97 |
| Radius Health, Inc. | 6 | $95 |
| Aurinia Pharma U.S., Inc. | 3 | $60 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $44 |
| Genentech USA, Inc. | 2 | $42 |
| Kyowa Kirin, Inc. | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Pfizer | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bioventus LLC | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Biocon Biologics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$224
- Rinvoq$211
- Tremfya$208
- Cimzia$205
- SIMPONI ARIA$127
- Otezla$123
- KEVZARA$106
- EVENITY$106
- PURIFIED CORTROPHIN GEL$101
How this compares
$15,462 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 17 | $144,683 |
| EnbrelEtanercept | 16 | $117,492 |
| RinvoqUpadacitinib | 17 | $106,086 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $105,232 |
| Enbrel SureclickEtanercept | 14 | $102,025 |
| Xeljanz XrTofacitinib Citrate | 18 | $100,777 |
| Actemra ActpenTocilizumab | 16 | $37,961 |
| Hydroxychloroquine Sulfate | 401 | $24,156 |
| MethotrexateMethotrexate Sodium | 269 | $8,994 |
| Mycophenolate Mofetil | 39 | $4,251 |
| Leflunomide | 67 | $3,766 |
| Sulfasalazine | 58 | $1,978 |
| Pilocarpine Hcl | 22 | $1,517 |
| Sulfasalazine DrSulfasalazine | 22 | $1,418 |
| Prednisone | 151 | $1,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $1,655 | $117,49216 claims |
| AbbVieRinvoq | $2,356 | $106,08617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Lansing
- Jason InmanLansing$14K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.